Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Increases Acute GVHD After Allo-HSCT

Biol Blood Marrow Transplant; ePub 2018 Jan 4; Hosoba, et al

Peri-transplant red blood cell (RBC) transfusions appear to increase the risk of developing severe acute graft-vs-host disease (aGVHD) and experiencing worse overall survival following allogeneic hematopoietic stem cell transplant (allo-HSCT), according to a retrospective study involving 322 individuals. Participants with hematological malignancies received RBC transfusion before either allogeneic bone marrow or granulocyte colony-stimulating factor-mobilized blood stem cell grafts. Among the results:

  • 1 in every 5 patients developed maximal grade of III-IV aGVHD.
  • Onset occurred up to 150 days post-transplant (median onset 28 days).
  • Patients with HLA mismatch and those with a higher number of RBC units were each >twice as likely to experience grade III-IV aGVHD.
  • High-risk patients and those receiving more median RBC units were independently linked with inferior overall survival.


Hosoba S, Waller E, Shenva N, et al. Peri-transplant RBC transfusion is associated with increased risk of GvHD after allogeneic stem cell transplantation. [Published online ahead of print January 4, 2018]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2018.01.003.

This Week's Must Reads

Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251

auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489

Low arginine linked to SFTS, Li X-K et al. Sci Transl Med. doi: 10.1126/scitranslmed.aat4162

Must Reads in Myelodysplastic Syndrome

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126

Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al

Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al